☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search
Search here
Search here
Subscribe Now
Triple Regimen
Novartis' Triple Regimen Fails to Meet the Primary Endpoint in P-III COMBI-i Study for Advanced Melanoma
August 25, 2020
Eli Lilly and Boehringer Ingelheim's Triple Regimen Receive the US FDA's Approval for Type 2 Diabetes
January 28, 2020
Celgene's Pomalyst (pomalidomide)-Based Triple Regimen Receive Health Canada's Approval for Multiple Myeloma
July 11, 2019
Load more...
Back to Home
Modal title
×
Modal body text goes here.